Convention vs. innovation I: Skin biopsy for synuclein inclusions should now be used in the clinical setting
- 1 May 2025
- journal article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107848
Abstract
No abstract availableFunding Information
- Abbott Laboratories
- Gordon and Marilyn Macklin Foundation
- National Institute of Neurological Disorders and Stroke
- Biohaven Pharmaceuticals
- Pfizer
- Merck Healthcare KGaA
This publication has 13 references indexed in Scilit:
- Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With SynucleinopathiesJAMA, 2024
- A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchThe Lancet Neurology, 2024
- Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's DiseaseMovement Disorders, 2023
- A comparative blind study between skin biopsy and seed amplification assay to disclose pathological α-synuclein in RBDnpj Parkinson's Disease, 2023
- Phosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophyBrain, 2023
- A case series of cutaneous phosphorylated α-synuclein in Long-COVID POTSClinical Autonomic Research, 2022
- The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy StudyJournal of Neuropathology & Experimental Neurology, 2022
- Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and ParkinsonismMovement Disorders, 2020
- Teaching Medical Students Basic Principles of Laboratory MedicineClinics In Laboratory Medicine, 2007
- Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutationMovement Disorders, 2006